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Abstract
We provide an evidence base and guidance for the use of menopausal hormone therapy (MHT) for the maintenance of skeletal
health and prevention of future fractures in recently menopausal women. Despite controversy over associated side effects, which
has limited its use in recent decades, the potential role for MHT soon after menopause in the management of postmenopausal
osteoporosis is increasingly recognized. We present a narrative review of the benefits versus risks of using MHT in the
management of postmenopausal osteoporosis. Current literature suggests robust anti-fracture efficacy of MHT in patients
unselected for low BMD, regardless of concomitant use with progestogens, but with limited evidence of persisting skeletal
benefits following cessation of therapy. Side effects include cardiovascular events, thromboembolic disease, stroke and breast
cancer, but the benefit-risk profile differs according to the use of opposed versus unopposed oestrogens, type of oestrogen/
progestogen, dose and route of delivery and, for cardiovascular events, timing of MHT use. Overall, the benefit-risk profile
supports MHT treatment in women who have recently (< 10 years) become menopausal, who have menopausal symptoms and
who are less than 60 years old, with a low baseline risk for adverse events. MHT should be considered as an option for the
maintenance of skeletal health in women, specifically as an additional benefit in the context of treatment of menopausal
symptoms, when commenced at the menopause, or shortly thereafter, in the context of a personalized benefit-risk evaluation.
Key messages • Overall the benefit-risk balance for MHT use is more
favourable at the age of menopause or in the years thereafter, for example
before the age of 60 years and/or within 10 years after menopause, and for
unopposed oestrogen (used in hysterectomized women) compared with
combined oestrogen plus progestogen in women with an intact uterus.
•There is some evidence that the risk of cardiovascular outcomes depends
upon age/time frommenopause, such that, particularly for oestrogen only
therapy, the risk of such outcomes may be lower when hormone therapy
is commenced early postmenopause compared with in older age. This
temporal relationship is less well-defined for combined oestrogen-
progestogen therapy.
• Transdermal preparations are associated with lower risk of thromboem-
bolic outcomes and are as effective as oral preparations for maintenance
of BMD, but their effect on fracture risk reduction is unproven.
• Overall, MHT may be considered as an option for the maintenance of
bone health in menopausal women, as an additional benefit in the context
of treatment of menopausal symptoms, amongst women who are at low
risk of breast cancer and of cardiovascular, cerebrovascular and venous
thromboembolic events and who do not warrant a specific skeletal ther-
apy such as a bisphosphonate.
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Introduction
Over the last three decades, osteoporosis has progressed from
being viewed as an inevitable consequence of ageing to being
understood as a major non-communicable chronic disease,
with an associated diagnostic definition and effective methods
of detection, risk stratification and treatment [1, 2]. We are
fortunate now to have a wide range of therapeutic strategies
for managing osteoporosis, targeted at improving or maintain-
ing bone mineral density [3, 4]. Across the various pharma-
ceutical interventions available, it is possible to view particu-
lar therapies as most appropriately targeted to particular stages
of the risk spectrum. For example, oral bisphosphonate thera-
py may be appropriate where there is established osteoporosis
and high risk of fracture [3]. In a recent position paper from
the European Society for the Clinical and Economic Aspects
of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases
(ESCEO) and the International Osteoporosis Foundation
(IOF), we described how this appreciation of stratification
according to efficacy, costs and side effects, in relation to
low, high and very high fracture risk, might be implemented
in clinical practice [5]. A key consideration in this work was
the approach to women who were currently at low risk but
who might well become at high risk in older age and whether
interventions based on the high lifetime risk of fracture, rather
than the immediate low risk of fracture, might be advised. One
class of medication that is highly relevant here is menopausal
hormone therapy (MHT), given the clear evidence for its anti-
fracture efficacy, regardless of baseline bone mineral density,
and also for the relevant ameliorative effects on menopausal
symptoms [6].
MHT was widely used in the 1980s and 1990s for the
prevention of symptoms associated with the menopause, such
as hot flushes, night sweats and sleep disturbance, with the
widely prevailing view that prevention of cardiovascular dis-
ease and osteoporosis were additional benefits [7, 8]. The
rationale for such an approach was an evidence-base
consisting principally of observational studies, in which the
use of hormone replacement therapy (as it was known at that
time) was associated with generally improved health out-
comes, particularly in relation to cardiovascular disease. This
whole thesis was challenged by results from the large US
Women’s Health Initiative (WHI) Hormone Therapy trials,
the first of which compared a fixed composition of conjugated
equine oestrogens (CEE) and medroxyprogesterone acetate
(MPA) to placebo and was published in 2002 [7, 9]. This trial
reported that, whilst this hormone therapy regimen did indeed
lead to a decreased risk of fractures, it was associated with
increased risks of cardiovascular and cerebrovascular events,
as well as with increased risks of breast cancer and other
adverse health outcomes [10]. Subsequently, the limitations
of inadequately analysed, confounded observational studies
and the potential for converse findings from well conducted
randomized controlled trials have found a key exemplum in
the MHT story [11]. Interestingly, when the original observa-
tional studies were re-analysed using state-of-the-art
pharmacoepidemiology techniques, which much more effec-
tively control problems such as confounding by indication,
then findings more in line with the results from randomized
trials were observed [11]. However, these remain analyses of
observational studies and therefore should be viewed as less
robust evidence than those derived from randomized trials.
Subsequent re-analyses of the WHI trials, together with evi-
dence from other trials, have suggested that the benefit-risk
profiles of MHT differ according to the timing of use in rela-
tion to the menopause and chronological age and by MHT
regimen (addition or not of progestogen, type of oestrogen
and progestogen, dose of oestrogen and route of administra-
tion) [7–9].
There is clearly a complex evidential landscape in which to
assess the role of MHT in the prevention/treatment of osteo-
porosis. In this position paper, based on a narrative literature
review, we will use randomized controlled trial evidence and
meta-analyses thereof, in order to use the best quality data.
Additionally, we focus on the scenario of normal menopause,
rather than premature ovarian insufficiency, for which MHT,
to replace the hormone deficit, is generally appropriate [12].
We firstly describe the natural history of the menopause in
terms of hormonal changes and consequent health outcomes;
subsequently, we set out the evidence that MHT is effective in
reducing the risk of incident fracture, the independence of this
effect from baseline BMD and age. Thereafter, we aim to
examine the overall benefit-risk profile of MHT, particularly
with regard to cardiovascular outcomes, and to investigate the
potential effects of timing in relation to menopausal transition,
dose and route of administration as approaches to mitigate
adverse effects. We conclude by assessing the potential health
economic aspects of the use of MHT for fracture prevention
and outline a potential clinical approach.
Natural history of hormonal changes
at the menopause and associated health
outcomes
Menopausal physiology
The menopause is defined as the permanent cessation of men-
struation that results from loss of ovarian follicular activity.
Clinically, in women in their 40s or 50s, it is recognized to
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have occurred after twelve consecutive months of
amenorrhoea for which no other obvious pathological or phys-
iological cause can be found. In most women, the menopause
is preceded by a phase of about 4 years during which the
endocrine, biological and clinical features of changing ovarian
function occur [13, 14]. In a normal menstrual cycle, the ova-
ries produce oestrogens (i.e. oestradiol), androgens (i.e. testos-
terone) and progesterone in a cyclical pattern under the control
of follicle stimulating hormone (FSH) and luteinizing hor-
mone (LH), which are secreted by the pituitary gland. In the
early menopausal phase (perimenopause), oestradiol levels
may remain relatively similar to those in young women (or
may even be higher), but cycles frequently become shorter or
irregular. The depletion of the ovarian reserve with age, a
consequence of the finite number of oocytes and the conse-
quent reduced levels of oestrogen, leads to an increase in
circulating follicle-stimulating hormone (FSH) and luteinizing
hormone (LH) levels. In contrast to the relatively rapid decline
in oestradiol during menopause, concentrations of total and
free testosterone, as well as of dehydroepiandrosterone sul-
phate (DHEAS) and androstenedione, appear to fall rather
more steadily with advancing age. Concentrations of proges-
terone are low postmenopause, and whilst circulating levels of
oestrogen are markedly lower post- than premenopause, there
may still be some oestrogenic activity at the intracellular level
as a result of local aromatization of androgen precursors [15].
These hormonal changes lead to the wide range of symptoms
associated with the menopause, such as hot flushes, sleep
disturbance, mood changes and urogenital changes, which
are described in detail elsewhere [16].
Menopause and the skeleton
In 1947, Fuller Albright published his observations on the
causal relationship between oestrogen deficiency following
the menopause and impaired bone health [17]. His work
established the principles that treatment with exogenous
oestrogen can help to maintain bone mass and thus to reduce
fracture risk. Oestrogen appears to have direct activity on os-
teoclasts, osteoblasts and osteocytes, with the principal effects
as an antiresorptive agent through reduction of osteoclast
numbers and function, mediated through various pathways
including the receptor activator of nuclear factor kappa B li-
gand (RANKL) system [18]. Impaired osteoblast activity in
oestrogen deficiency is reflected in reduced matrix production
as measured by mean wall thickness on bone histology, an
effect that is reversed by oestrogen replacement [19]. The
increase in fracture risk associated with the menopausal tran-
sition is well established, together with a period of accelerated
bone loss, particularly trabecular (with a loss of bone struc-
ture, for example increased trabecular perforations, as well as
loss of bonemass [20]), which then settles to a more long-term
age-related decline. Interestingly, the presence of menopausal
symptoms has been shown to be associated with spinal oste-
oporosis, supporting a dual benefit of MHT on both outcomes
[21]. The incidence of fracture varies by age and site, such that
wrist fractures become notable around the age of menopause
and in the years soon after, whereas the incidences of vertebral
and then hip fractures rise sharply at older ages [22, 23]. A
wrist fracture may well be the warning sign for impaired bone
health in the recently menopausal woman, and thus indicate
the urgent necessity for risk assessment and preventive action
to prevent further fracture events [22].
Types of MHT (oestrogens, progestogens,
dose, route of administration)
MHT in its simplest form consists of an oestrogen, given either
alone (where a woman has undergone hysterectomy) or togeth-
er with a progestogen to reduce the risk of endometrial cancer
where the uterus is still present. For example, the combination
used in the WHI was oral conjugated equine oestrogen (CEE)
0.625 mg/day and medroxyprogesterone acetate (MPA)
2.5 mg/day. However, there is now a wide range of options,
including other more physiological oestrogen compounds, such
as oral micronized 17β-oestradiol (typically at a dose of 1–
2 mg/day), and other progestogens, such as norethisterone ace-
tate, micronized progesterone or dydrogesterone. Additionally,
there are preparations that can be administered via the transder-
mal or percutaneous route (for example transdermal 17β-
oestradiol typically at 25–50 μg/day), and across routes of ad-
ministration, various doses are now available [24]. Transdermal
absorption of oestrogen bypasses first pass metabolism in the
liver and appears not to alter the risk of venous thromboembolic
disease and stroke, certainly much less than do oral oestrogens
[25, 26].Whilst the progestogen component ofMHT is given to
reduce the risk of endometrial cancer, it should be noted that the
benefit-risk profile of unopposed and opposed oestrogen MHT
is rather different [8]. Finally, for completeness, tibolone (a
synthetic steroid with mixed oestrogenic, progestogenic and
androgenic activity) [27] and TSEC (Tissue Selective
Oestrogen complex containing CEE and bazedoxifene) are also
available for menopause treatment, although, as with other
medications, their use and availability vary from country to
country [24]. Given these complexities, it is critical to take a
particular MHT preparation on its ownmerits and individualize
treatment as far as the evidence will permit. For more specific
information regarding doses and preparations, the reader is di-
rected elsewhere [16].
Efficacy of MHT for fracture prevention
The initial seminal intervention studies, undertaken by
Christiansen and colleagues in relatively small numbers of
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women, demonstrated protective effects of oestrogen with or
without progestogen on bone mass, assessed using single or
dual photon absorptiometry [28–30]. A US trial additionally
demonstrated effects on bone histomorphometric parameters
[31]. The first randomized trial evidence using dual-energy X-
ray absorptiometry (DXA) to show that MHT maintains bone
mineral density (BMD) after the menopause came from the
Postmenopausal Oestrogen/Progestin Intervention (PEPI) tri-
al, published in 1996 [32]. It was the results of the WHI that
demonstrated the anti-fracture efficacy of MHT, a finding that
applied to all osteoporosis-related fractures, including those at
the hip, and importantly in a population that was unselected
for low BMD. Thus, amongst the 16,608 women aged 50–
79 years with an intact uterus at baseline who were random-
ized to either CEE+MPA or matching placebo, over a mean of
5.2 years follow-up, there was a 34% reduction in the inci-
dence of hip fracture [Hazard Ratio (HR): 0.66; 95% CI: 0.45
to 0.98]. A very similar effect was observed on the incidence
of clinical vertebral fractures and a reduction in other osteo-
porotic fractures was documented (HR: 0.77; 95% CI: 0.69 to
0.86) [10]. A second analysis with 5.6 years of follow-up on
active treatment again demonstrated a statistically significant
reduction in fracture risk for the CEE+MPA group compared
with placebo (HR: 0.76; 95% CI: 0.69 to 0.83). This effect
was not modified by a range of factors such as age, body mass
index, smoking status, prior falls, personal/family history of
fracture, total calcium intake, past use of hormone therapy and
importantly was independent of baseline BMD. A 3.7% in-
crease in total hip BMD was noted at 3 years of treatment
compared with a 0.14% increase in the placebo group [33].
The persistence, or otherwise, of a bone protective effect of
MHT is an important consideration for its place in osteoporo-
sis management. In a small early study, women (n = 347) who
had previously been enrolled in one of four placebo-controlled
MHT trials were re-examined at 5, 11 or 15 years after stop-
ping MHT [34]. Here, although rates of bone loss after stop-
ping MHT returned to normal postmenopausal values, the
BMD of previouslyMHT-treated women continued, for many
years after cessation of treatment, to be higher than that of
women who had received placebo. Furthermore, the risk of
all osteoporotic fractures was lower in the previously MHT-
treated than previously placebo-treated group [34]. However,
several other studies both at the mechanistic [35] and popula-
tion level have suggested that protective skeletal effects of
MHT do not convincingly persist after cessation of therapy.
Thus, amongst 140,584 postmenopausal women who partici-
pated in the US National Osteoporosis Risk Assessment
study, those women who had discontinued MHT in the past
5 years had a 1-year hip fracture risk similar to women who
had never usedMHT [36]. Similar findings came from a study
using the US Southern California Kaiser Permanente health
management organization database. A total of 80,955 post-
menopausal women using MHT were followed for around
6.5 years [37]. Women who discontinued MHT were at 55%
greater risk of hip fracture compared with those who contin-
ued, with the risk increasing as early as 2 years after cessation
of MHT. Clearly, these observational studies may be more
prone to bias and confounding than randomized trials.
However, in the WHI, 3 years after cessation of the MHT
intervention [38], in further analyses at a median follow-up
of 4.8 years postintervention [39] and then in extended follow-
up (8.2 years CEE+MPA and 6.6 years CEE only) postinter-
vention, there was no evidence of any residual benefit from
prior MHT for hip fractures, although rates were lower in the
intervention than placebo group across the combined interven-
tion and post-intervention follow-up [39, 40]. A further
fracture-focused WHI analysis, examining women during
5 years of postintervention follow-up, who had been previous-
ly randomized to MHT or placebo again found that there was
no evidence of either transiently or persistently decreased frac-
ture risk amongst former MHT users compared with former
placebo users. However, there was some evidence of a
persisting benefit on total fractures amongst former MHT
users who had taken part in the CEE-alone trial (who had
undergone hysterectomy prior to baseline) but not in the
CEE+MPA trial [41].
The WHI programme, with its several trials randomizing
women to MHT versus placebo and calcium+vitamin D sup-
plementation versus placebo, yielded a total of 16,089 women
inwhom an interaction betweenMHT and calcium+vitamin D
supplementation on fracture risk reduction could be investi-
gated. Indeed, there was evidence of an interaction between
hormone therapy and calcium+vitamin D supplementation on
hip fracture (p-interaction = 0.01). The effect of calcium+vita-
min D supplementation was greater amongst women assigned
to MHT (HR: 0.59; 95%CI: 0.38 to 0.93) than placebo (HR:
1.20; 95%CI: 0.85 to 1.69). Furthermore, the effect of hor-
mone therapy (vs hormone therapy placebo) on hip fracture
was greater amongst women assigned to calcium+vitamin D
supplementation (HR: 0.43; 95%CI: 0.28 to 0.66) than those
women assigned to the placebo of the calcium+vitamin D
randomization (HR: 0.87; 95%CI: 0.60 to 1.26).
Interestingly, there was no apparent interaction of MHT with
calcium+vitamin D supplementation on hip or spine BMD
changes, leading to questions regarding the underlying mech-
anism. However, the findings do suggest a synergistic benefit
between these two interventions on fracture reduction [42].
Finally, in a meta-analysis of 28 studies including 33,426
participants and 2516 fracture cases, bone protective effects
were consistent with those observed in WHI, with the HR for
all fractures (MHT vs placebo) 0.74; 95%CI: 0.69 to 0.80.
Effect sizes were similar for hip (HR: 0.72; 95% CI: 0.53 to
0.98) and vertebral (HR: 0.63; 95% CI: 0.44 to 0.91) fractures
[43]. Studies examining lower doses and transdermal applica-
tions (for example doses of 0.3 mg/day oral conjugated
oestrogens, 0.25 mg/day oral micronized 17β-oestradiol or
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14 μg/day transdermal oestradiol) have suggested positive
effects on bone mineral density, but definitive fracture out-
come data are scarce [24, 44].
Safety profile of MHT
Women’s Health Initiative: overview and key findings
The Women’s Health Initiative (WHI) hormone studies com-
prised two MHT randomized controlled trials, including
27,347 postmenopausal women age 50–79 years [7, 8].
Although these women were a generally healthy population,
it should be noted that 35% had treated hypertension, 50%
were past/current smokers and 34% had a body mass index
greater than 30 kg/m2 [10]. In order to accommodate the
established risk of unopposed oestrogen for endometrial can-
cer, women with an intact uterus (n = 16,608) were random-
ized to conjugated equine oestrogens (CEE) 0.625 mg/day,
together with an oral progestin [medroxyprogesterone acetate
(MPA) 2.5 mg/day) or placebo. Those women who had had a
hysterectomy (n = 10,739) were included in the oestrogen
alone trial, with randomization to CEE 0.625 mg/day versus
matched placebo. The aim of these trials was to assess the
impact of MHT on chronic non-communicable diseases of
ageing such as cardiovascular outcomes, and therefore the
sample sizes were chosen to have sufficient power to detect
an effect on a composite outcome of coronary heart disease
[non-fatal myocardial infarction (MI) or coronary death] and to
assess the balance of benefits and risks over an 8.5 year treat-
ment period. In fact, the two trials were stopped earlier than
planned with the oestrogen-progestin trial halted after a median
of 5.6 years of treatment (as a result of an observed increase in
risk of breast cancer); the oestrogen alone trial was stopped
after median of 7.2 years because of an increased risk of stroke
in the CEE arm. The investigators continued to follow the
participants for several years after cessation of the intervention
and thus in the combined trial, median follow-up post inter-
vention was 8.2 years; in the CEE alone trial, median post-
intervention follow-up was 6.6 years. The findings from
WHI completely altered the clinical approach to MHT, with
the prevalence of hormone therapy use in the US and Europe,
declining sharply after publication of the first results in 2002.
Data from the US National Health and Nutrition Examination
Survey demonstrated a 22.4% prevalence of MHT use 1999 to
2000, declining to 11.9% in 2003–2004 with a more gradual
further decline to 4.7% in 2009–2010 [45].
Thus, whilst the observational studies that preceded WHI
had suggested a protective effect of MHT for cardiovascular
outcomes; in the WHI trials, there was a modest increase in all
cardiovascular events in women treated with hormone thera-
py. This was observed both with CEE+MPA (Hazard Ratio
(HR): 1.13; 95%CI: 1.02 to 1.25) and with CEE alone (HR:
1.11; 95%CI: 1.01 to 1.22) during the intervention phases of
the trials. The signal was also observed in the extended
follow-up covering 13 years, with the HR (CEE+MPA):
1.08; 95% CI: 1.00 to 1.15 and HR (CEE alone): 1.06;
95%CI 0.98 to 1.15 [40]. Interestingly, during the first year
of follow-up, there was an 80% increased risk of coronary
heart disease events (non-fatal myocardial infarction or
coronary death) with CEE+MPA compared with placebo,
but which tapered off with time on treatment, a secular effect
that was statistically significant (p = 0.03) [8]. It should be
noted that the original analyses also included adjusted 95%
CI to account for the repeated assessments of coronary heart
disease (and breast cancer) outcomes and that these confi-
dence intervals generally spanned unity. However, the inves-
tigators emphasized the unadjusted confidence intervals as the
primary outcomes, which appears appropriate given the po-
tential evidence for adverse effects [10]. A similar pattern of
findings was observed in the final analysis of cardiovascular
outcomes in the CEE+MPA trial, published a year later, with
the absolute event rates for coronary heart disease events dem-
onstrating the small excess in terms of absolute risk with 39
cases per 10,000 person-years in the hormone therapy and 33
per 10,000 person-years in the placebo group [46]. Venous
thromboembolism was increased with both types of MHT,
although more so with CEE+MPA. Thus, the HR for pulmo-
nary embolism in the CEE+MPA trial was 1.98; 95%CI: 1.36
to 2.87, and in the same trial, the HR for deep vein thrombosis
was 1.87; 95%CI: 1.37 to 2.54. The corresponding HRs in the
CEE alone trial were 1.35; 95%CI: 0.89 to 2.05 and 1.48;
95%CI: 1.06 to 2.07 for pulmonary embolism and deep-vein
thrombosis, respectively [40]. The HR for stroke with CEE+
MPA vs placebo was 1.37; 95%CI: 1.07 to 1.76 and with CEE
alone vs placebo, 1.35; 95%CI: 1.07 to 1.70. The other major
concern arising from WHI was the increased risk of breast
cancer for women randomized to CEE+MPA compared with
placebo (HR: 1.24; 95%CI: 1.01 to 1.53), which remained
elevated during cumulative follow-up (HR: 1.28; 95%CI:
1.11 to 1.48). Interestingly (and consistent with other data)
[24], randomization to CEE alone was associated with a re-
duced risk (HR: 0.79: 95%CI: 0.61 to 1.02), which persisted
with time. Over the entire follow-up (after a mean of
10.7 years), lower breast cancer incidence in the CEE group
persisted and was 0.27% compared with 0.35% in the placebo
group (HR, 0.77; 95%CI: 0.62 to 0.95) [39]. Conversely,
CEE+MPA was associated with a reduction in colorectal can-
cer (HR: 0.62; 95%I: 0.43 to 0.89) and evidence of a more
modest reduction in endometrial cancer (HR: 0.83; 95%CI:
0.49 to 1.40). With both MHT regimens, there were reduc-
tions in the risk of hip fracture, all fractures and type II diabe-
tes, but an increase in gall bladder disease, urinary inconti-
nence and the risk of dementia (only assessed in an older
subset). In neither trial was the MHT intervention associated
with mortality [40].
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Finally, the pattern of cardiovascular events following dis-
continuation of MHT deserves consideration. Thus, amongst
332,202 Finnish women discontinuing MHT between 1994
and 2009, with data derived from national registries, previous
MHT users had greater risk of cardiac (standardized mortality
ratio (SMR), 95%CI: 1.26; 1.16 to 1.37) and stroke death
(1.63; 1.47 to 1.79) than expected over the first year post
MHT cessation, but a lower risk thereafter (SMR: 0.75;
95%CI: 0.72 to 0.78 and 0.89; 0.85 to 0.94 respectively).
Interestingly, the first year excess mortality seemed greater
for women who had been < 60 years old at MHT initiation
or been users for < 5 years, supporting the notion of differ-
ences in cardiovascular effects of MHT by age. The risk of
both outcomes was consistently greater in those women who
stopped MHT compared with those continuing [47]. A further
analysis from the same group using national Finnish registry
data and excluding women who experienced a cardiac or ce-
rebrovascular event within the year before treatment cessation
demonstrated similar excess mortality in the first year after
stopping MHT compared with an age-matched female back-
ground population [48]. Although these observational find-
ings do not prove a causal relationship and indeed may be
influenced by, for example, cardiovascular/cerebrovascular
related reasons for stopping (although the authors attempted
to control for this in the later paper), these results do further
support the vascular relevance of MHT.
MHT and cardiovascular outcomes: does timing make
a difference?
A key consideration in the interpretation of the results of the
WHI trial is that the average age of the participants was
63 years, which is markedly older than the average age of
menopause in North America or Europe (51 years) [8].
Indeed, the majority of the WHI participants did not have
symptoms of the menopausal transition [7]. This contrasts
with the majority of the preceding observational studies,
which generally enrolled younger women closer to the onset
of menopause and usually with menopausal symptoms. The
WHI investigators undertook analyses stratified by age, that
is, effectively by years since menopause [8, 40]. The findings,
of a more favourable benefit-risk profile for those within
10 years of the menopause, compared with those womenmore
than 10 years after menopause, have led to the concept of the
“timing hypothesis” in relation to cardiovascular outcomes
[8]. In this context, cardiovascular refers to arterial disease
rather than to venous thromboembolism. Thus, in the WHI,
when stratified by age, there was actually a reduction in myo-
cardial infarction [HR: 0.55; 95%CI: 0.31 to 1.00) and all-
cause mortality (HR: 0.70; 95%CI: 0.46 to 1.09) in the 50–
59 year age band for CEE alone compared with placebo. In
contrast, those in the oldest age band (70–79 years) tended
towards increased risks of these outcomes (HR: 1.24;
95%CI: 0.88 to 1.75 and HR: 1.21; 95%CI: 0.95 to 1.56 for
myocardial infarction and total mortality respectively).
Although there were differences by age band for the CEE+
MPA trial, these were not so obviously linear, with the lowest
hazard ratios usually in the 60–69 year age band compared
with 50–59 years and 70–79 years. Interestingly, there ap-
peared to be no effect by age band on relationships with
stroke, breast cancer, fractures, diabetes or thromboembolic
disease across either of the two hormone therapy regimens
[40]. Indeed, breast cancer remains the other particularly
concerning side effect of opposedMHT, and although beyond
the scope of this review, the relevant evidence is discussed in
detail elsewhere [16, 24]. Figure 1 summarizes the absolute
differences per 5000 person-years (1000 persons treated over
5 years) in number of events in the WHI hormone trials for
women aged 50–59 years at enrolment.
The timing hypothesis in trials subsequent to WHI
Other intervention studies have investigated whether use of
MHT early after the menopause might have protective effects
on coronary artery disease, using measures of atherosclerosis
such as carotid intima-media thickness and coronary artery
calcification (summarized in Table 1). The majority of these
were conducted post-WHI, but the Heart and Estrogen/
progestin Replacement Study (HERS) Research Trial yielded
earlier relevant insights, albeit in the context of secondary
prevention. A total of 2763 women with established coronary
heart disease, who were younger than 80 years old (mean age
66.7 years) and postmenopausal with an intact uterus, were
recruited across outpatient and community settings in 20 US
clinical centres [49]. Women were randomized to either
0.625 mg CEE plus 2.5 mg of MPA (n = 1380) or matched
placebo (n = 1383). Overall, there were no significant differ-
ences between groups in the primary outcome of non-fatal
myocardial infarction or coronary heart disease (CHD) death
[Relative hazard (RH), 0.99; 95% CI: 0.80 to 1.22] or in any
of the secondary cardiovascular outcomes. There was a net
11% lower low-density lipoprotein cholesterol level and
10% higher high-density lipoprotein cholesterol level in the
hormone group compared with the placebo group. Within the
overall null effect, there was a statistically significant time
trend, with more CHD events in the hormone group than in
the placebo group in year one and fewer in years four and five.
More women in the hormone group than in the placebo group
experienced venous thromboembolic events (34 vs 12; RH:
2.89; 95% CI: 1.50 to 5.58) and gallbladder disease (84 vs 62;
RH: 1.38; 95% CI: 1.00 to 1.92). So here across the mean
4.1 years follow-up, there was a null effect on cardiovascular
endpoints overall but with evidence of greater risk early dur-
ing follow-up and reduced risk later, as well as an increased
risk for venous thromboembolic events [49]. Given the poten-
tial for loss to follow-up and reduced adherence with time (for
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example those who experienced a myocardial infarction in
year 1 may have left the trial subsequently), any inferences
about longer term treatment with MHT should be made with
caution. However, 82% of those assigned to hormone treat-
ment were taking it at the end of 1 year and 75% at the end of
3 years, and in fact outcome data were available on 100%
participants. A total of 2321 women (93% of those surviving)
consented to further unblinded follow-up over 2.7 years. The
overall RHs for non-fatal myocardial infarction and death due
to coronary heart disease, after adjustment for potential con-
founders and differential use of statins between treatment
groups (RH: 0.97; 95% CI: 0.82 to 1.14), and in analyses
restricted to women who were adherent to randomized treat-
ment assignment (RH: 0.96; 95% CI: 0.77 to 1.19) did not
provide any evidence of altered CHD risk during the addition-
al follow-up [50]. It is notable that the percent participants
who were > 80% adherent to allocated MHT fell from 81%
at year one to 45% in year six, and MHT use in the placebo
group increased from 0 to 8% over the same time period,
indicating reduced power to detect differences by original
treatment allocation.
In theKronos Early Oestrogen Prevention Study (KEEPS),
healthy menopausal women aged 40–58 years who were be-
tween 6 and 36 months from the last period and without pre-
vious cardiovascular events, were randomized to either oral
CEE (0.45 mg/day) or transdermal 17β-oestradiol (t-E2),
50 mcg/d, each with 200 mg of oral progesterone for 12 days
per month or placebo for 48 months [51, 52]. Over the 4-year
treatment, amongst 727 women randomized, there was no
evidence that hormone therapy, of either type, led to increases
in carotid intimamedia thickness (CIMT) or in coronary artery
calcium score, but the trial was not powered to detect differ-
ences in clinical outcomes. In this study, neither MHT inter-
vention was associated with alterations to blood pressure, in
contrast to oral CEE in WHI, although randomization to t-E2
was associated with decreased insulin resistance. The oral
CEE dose in KEEPS (which was lower than that in WHI)
was associated with a favourable change in lipid profile in
the sense that there was an increase in high-density lipoprotein
and decrease in low-density lipoprotein cholesterol; however,
there was an associated increase in triglycerides [51, 52].
In the Early versus Late Postmenopausal Treatment with
Estradiol randomised trial (ELITE), a total of 643 healthy
postmenopausal women were randomly assigned to receive
either oral 17β-oestradiol (1 mg/day) plus progesterone
(45 mg) vaginal gel administered sequentially (once daily
for 10 days of each 30-day cycle) for women with a uterus
or placebo (plus sequential placebo vaginal gel for women
without a uterus) [53]. Randomization was stratified accord-
ing to time since menopause (less than six years or ≥ 10 years).
Over a median of 5 years, the effect of 17β-oestradiol with or
without progesterone on CIMT progression was different ac-
cording to commencement early or late after the menopause.
The interaction was statistically significant (p = 0.007). Thus,
Fig. 1 Updated summary of the
effects of orally administered
CEE alone or combined with
MPA in women ages 50–59 years
during intervention phase of WHI
(reused with permission from [9])
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for those women in the early postmenopausal stratum, the
mean CIMT increased by 0.0078 mm per year in the placebo
group compared with 0.0044 mm per year in the 17β-
oestradiol group (p = 0.008). In the late postmenopausal stra-
tum, the rates of CIMT progression were similar between
placebo and intervention groups (p = 0.29). Measures of cor-
onary artery calcification, total stenosis and plaque from the
computed tomography assessments did not differ according to
randomization group [53].
The Danish Osteoporosis Prevention Study (DOPS) spe-
cifically addressed the issue of treatment with MHT soon
after the menopause [54]. In this open-label, randomized
controlled trial, 1006 healthy women aged 45–58 years
(mean 50 years) who were recently postmenopausal (mean
7 months) were randomized to receive menopausal hormone
therapy (n = 502) or no treatment (n = 504). In the treatment
group, women with an intact uterus were treated with
triphasic oestradiol and norethisterone acetate; women who
Table 1 Non-WHI key randomized controlled trials of MHT and main outcomes
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had undergone hysterectomy received 2 mg oestradiol per
day. The trial was stopped after around 11 years as a result
of the adverse event signals from the WHI, but the DOPS
investigators continued to follow participants for death, car-
diovascular and cancer outcomes for up to 16 years. After
10 years of intervention, 16 women in the treatment group
experienced the primary composite endpoint (death, admis-
sion to hospital for heart failure or myocardial infarction)
compared with 33 in the control group (HR: 0.48; 95% CI:
0.26 to 0.87) and 15 vs 26 died (HR: 0.57; 95%CI: 0.30 to
1.08), consistent with a protective effect of MHT. There was
no evidence of an increase in any cancer (intervention vs
control: 36 vs 39; HR: 0.92; 95%CI: 0.58 to 1.45) or in breast
cancer (10 vs 17; HR: 0.58; 95%CI: 0.27 to 1.27). The HR
for deep vein thrombosis (2 vs 1) was 2.01; 95%CI: 0.18 to
22.16 and for stroke (11 vs 14) was 0.77; 95%CI: 0.35 to
1.70. After 16 years, the reduction in the primary composite
outcome was still present and not associated with an increase
in any cancer [54]. However, despite the use of hard end-
points, the open-label nature of the trial design does not
necessarily warrant the same level of confidence as would
be associated with a truly double-blind structure.
The Women’s International Study of long Duration
Oestrogen after Menopause (WISDOM) trial was stopped ear-
ly after a median of 11.9 months recruitment as a result of the
findings from the WHI [55]. A total of 6498 women had been
enrolled, with a mean age similar to that of women in the WHI
(62.8 years). A total of 2196 womenwere randomized to either
oestrogen only therapy (CEE 0.625 mg orally daily) or com-
bined hormone therapy (CEE plus MPA 2.5/5.0 mg orally
daily) and 2189 to matched placebo. Consistent with findings
from theWHI, there was a significant increase in the number of
major cardiovascular events (7 vs 0; HR p = 0.016) and venous
thromboembolism (22 vs 3; HR: 7.36; 95% CI: 2.20 to 24.60)
in the combined HT group vs placebo. There were no statisti-
cally significant differences in numbers of breast or other can-
cers (22 vs 25; HR: 0.88; 95%CI: 0.49 to 1.56), cerebrovascu-
lar events (14 vs 19; HR: 0.73; 95%CI: 0.37 to 1.46), fractures
(40 vs 58; HR: 0.69; 95%CI: 0.46 to 1.03) and overall deaths
(8 v 5; HR: 1.60; 95%CI: 0.52 to 4.89). Comparison of com-
bined hormone therapy (n = 815) versus oestrogen therapy
(n = 826) outcomes revealed no significant differences; the
numbers of events were relatively low compared with WHI.
Finally a meta-analysis of 23 MHT trials, including
39,049 participants followed for 191,340 patient-years,
showed that hormone therapy appeared to significantly re-
duce CHD events in younger (mean time postmenopause <
10 years or age < 60 years) women [Odds ratio (OR): 0.68;
95%CI: 0.48 to 0.96], but not in older women (OR: 1.03;
95%CI: 0.91 to 1.16). In older women, hormone therapy
increased CHD events in the first year (OR: 1.47; 95%CI:
1.12 to 1.92) then reduced events after 2 years (OR: 0.79;
0.67 to 0.93) [56].
How might MHT differentially influence ischaemic
cardiovascular outcomes by age?
The concept that oestrogen might differentially influence
cardiovascular risk depending upon time since menopause,
or chronological age, originated in animal studies of non-
human primates. Thus, in cynomolgus monkeys, conjugated
oestrogens with or without MPA were not associated with
any changes in coronary artery plaques when the hormone
therapy was commenced at 2 years (equivalent to around 6
human years) after oophorectomy and in the presence of
established atherosclerosis. In contrast, this intervention re-
duced plaque size by 70% when initiated immediately fol-
lowing oophorectomy in the early stages of atherosclerosis
[57]. These findings are consistent with the results of the
KEEPS, ELITE and DOPS trials described above and of
human imaging trials in participants with significant coro-
nary lesions at baseline in which oestrogen appeared not to
slow the rate of arterial narrowing [58–61]. In contrast, a
protective effect of oestrogen on coronary artery atheroscle-
rosis was observed in a further imaging trial in which severe
coronary artery lesions were not a criterion for enrolment
[62]. These findings suggest that oestrogen might have dif-
ferential effects on the progression of atherosclerotic disease
and/or thrombotic events depending upon the degree of
baseline atherosclerotic disease. There is evidence that
oestrogen may increase nitric oxide synthesis and thus vaso-
dilation and potentially decrease inflammatory cell adhesion
and thus slow the progression of atherosclerotic plaques, in
the setting of healthy arteries, which of course are more
likely in younger patients closer to the menopause. In older
women with substantial atherosclerotic plaque, oestrogen re-
ceptors may become less responsive and there is some evi-
dence that oestrogen may adversely affect established ath-
erosclerotic plaques, rendering them more susceptible to rup-
ture and subsequent thrombotic occlusion of the blood ves-
sel [63]. Findings from WHI in relation to lipid status are
consistent with these hypotheses. Thus, CEE with or without
MPA was associated with a 40% lower risk of incident
coronary heart disease amongst women with a favourable
LDL/HDL ratio, but risk of these outcomes was greater in
women with an adverse LDL/HDL ratio at baseline [64].
Furthermore, the risk of coronary heart disease outcomes
associated with hormone therapy was more than double in
those with metabolic syndrome compared to those without
[65]. Again, within the WHI, measurements of coronary
artery calcium amongst women aged 50–59 years were low-
er amongst women assigned to oestrogen alone than
amongst those assigned to placebo [66]. As with all analyses
of subsets within the overall randomized trial population,
such investigation should be interpreted with caution given
their secondary nature and that randomization of covariates
may not be preserved.
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Use of MHT for maintenance of bone health
Health economics
The cost-effectiveness of MHT has been examined in relation to
the treatment of menopausal symptoms and for fracture preven-
tion in asymptomatic women but who are at high risk of a fra-
gility fracture. Zethraeus et al. incorporated the emerging data on
efficacy and side effects from WHI into an individual state tran-
sition model of 50- to 60-year-old women with menopausal
symptoms using a societal perspective in Sweden [67]. The
group undertook a similar analysis for a population based in
the UK using aMarkov cohort simulation model in women aged
50 years with clinical effectiveness and side effects informed by
the WHI [68]. In both of these studies, together with an analysis
based on the US population [69], there was evidence of cost-
effectiveness. The severity of menopausal symptoms was the
most and only one important determinant of cost-effectiveness,
but MHT remained cost-effective even where symptoms were
mild or the effects on symptom relief was small [68]. A further
analysis focused on women at high risk of fracture, but no men-
opausal symptoms, in Sweden, the US and the UK, with the
clinical effects again based on the findings from the WHI [70].
The state transition model had a lifetime horizon with disease
states across fracture, cancer and cardiovascular outcomes. The
results demonstrated thatMHTwas cost-effective comparedwith
no treatment for the majority of subgroups of hysterectomized
women. In contrast, for women with an intact uterus without a
prior fracture, the evidence for cost-effectiveness was less clear.
In this analysis, fracture risk was the single most important de-
terminant of the cost-effectiveness findings [70]. Thus, when
fracture risk was taken into account rather than menopausal
symptoms, use of MHT was cost-effective in women who had
had a hysterectomy irrespective of prior fracture status. In con-
trast, amongst women with an intact uterus, opposed MHT was
cost-effective only in thosewith a prior vertebral fracture. Overall
then, these data favour the use of MHT for prevention of meno-
pausal symptoms but do not clearly support a specific role in
fracture prevention, particularly in low fracture risk individuals.
A further caveat is that the analyses do not account for time since
menopause, which would be expected to improve cost-effective-
ness, and it is clearly important not to automatically conflate cost-
effectiveness with clinical appropriateness.
Existing guidelines
The notion that MHT might be an appropriate first line therapy
for the maintenance of bone health in recently postmenopausal
women is consistent with that proposed in several current
guidelines internationally. Thus the European Menopause and
Andropause Society (EMAS) states that “Administration of
systemic MHT has a favourable risk–benefit profile for women
under the age of 60 years or within 10 years after menopause for
menopausal symptoms and osteoporosis” [71]. The North
American Menopause Society (NAMS) acknowledges the ef-
fect of age post menopause on the risk-benefit landscape and
explicitly cites skeletal health as a consideration: “For women
aged younger than 60 years or who are within 10 years of
menopause onset and have no contraindications, the benefit-
risk ratio is most favourable for treatment of bothersome vaso-
motor symptoms and for those at elevated risk for bone loss or
fracture.” [72] This approach is also incorporated into guidance
from the International Menopause Society (IMS) [73]. The
American Association of Clinical Endocrinologists recommend
that “MHT should be used for the prevention and treatment of
osteoporosis within the context of the overall benefit-versus-
risk analysis of each patient” but also that “MHT should be
used in the lowest dose and for the shortest period necessary
to control menopausal symptoms” [74]. In contrast, the
American College of Obstetricians and Gynaecologists focuses
on menopausal symptoms [75], and lowest dose, shortest time
paradigm (to adequately control menopausal symptoms), with
theUSEndocrine Society suggesting that there is no support for
using MHT to prevent coronary heart disease, breast cancer or
dementia, but with ambivalence towards fracture prevention
[76]. A 2016 Global Consensus Statement, endorsed by IMS,
NAMS, The Endocrine Society, EMAS, The Asia Pacific
Menopause Federation, The International Osteoporosis
Foundation and The Federation of Latin American
Menopause Societies, explicitly proposed that “MHT…can be
initiated in postmenopausal women at risk of fracture or osteo-
porosis before the age of 60 years or within 10 years after
menopause” but that “Initiation of MHT after the age of 60
years for the indication of fracture prevention is considered
second-line therapy and requires individually calculated bene-
fit/risk, compared to other approved drugs. If MHT is elected,
the lowest effective dose should be used.” [77] Finally clinical
guidance from the UK National Institute for Health and Care
Excellence (NICE) focuses on the use of MHT for postmeno-
pausal symptoms and suggests that under the age of 60 years,
the risks of cardiovascular disease are negligible for oestrogen
only MHT and that there is little or no increased risk of coro-
nary heart disease with combined MHT. Again, an individual-
ized approach accommodating baseline cardiovascular risk is
recommended, together with consideration of other factors such
as history of breast cancer and thromboembolic disease [16].
Clinical approach
Osteoporosis is now a well-defined morbidity, with associated
diagnostic criteria, methods of detection and, importantly, a
range of effective treatment modalities [22]. Approaches to
detection and assessment of individuals at low, high and very
high risk of experiencing an osteoporotic fracture have been
recently set out in detail by the European Society for Clinical
and Economic Aspects of Osteoporosis, Osteoarthritis and
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Musculoskeletal Diseases (ESCEO) and the International
Osteoporosis Foundation (IOF) [5], building on the 2019
European Guidance for Assessment and Treatment of
Postmenopausal Osteoporosis from the same societies [4].
The stratification of management approach according to risk
level accommodates the nuances of the range of medications
currently available, encompassing interventions including cal-
cium and vitamin D supplementation all the way through
bisphosphonates up to anabolic therapies. Within this frame-
work, MHT is considered as a potential preventative interven-
tion as the initial part of a longer term management strategy
for those postmenopausal women found to be at low risk of
fragility fracture over the next 10 years, using the FRAX®
algorithm, but who of course may have a much greater re-
maining lifetime risk (Fig. 2) [5]. In this setting, a specific
bone therapy (for example a bisphosphonate) may not be ap-
propriate, and the question is, on the one hand, whether the use
of MHT should be specifically indicated for the maintenance
of bone health and prevention of fractures or, on the other
hand, whether fracture risk reduction should be viewed as an
additional benefit from a medication used for treatment of
menopausal symptoms. Ultimately, this depends on the indi-
vidual balance of benefits versus risks: the current literature
suggests robust anti-fracture efficacy of MHT in patients un-
selected for low BMD, regardless of concomitant use with
progestogens, but with little evidence for persisting benefits
following cessation of therapy. The risks appear to vary ac-
cording to age/time of use, with potential cardiovascular ben-
efits for unopposed oestrogen (in hysterectomized women)
used within 10 years after the menopause in WHI, and null
effects for opposed oestrogen in KEEPS, but potential cardio-
vascular benefits when initiated close to the menopause in the
ELITE and DOPS Trials. Other side effects such as deep-vein
thrombosis, stroke and gall bladder disease are raised to a
greater or lesser extent according to use of opposed or unop-
posed oestrogen, dose and route of administration, and should
all be considered. Breast cancer remains a key consideration
with combined MHT [16, 24]. Although there is clearly con-
cern with regard to side effects of MHT, these must be under-
stood in the context, firstly, of the absolute risks of such events
in the menopausal population, and secondly, of the benefit-
risk balance for other medications used in osteoporosis treat-
ment. For example, a UK 50-year-old woman with no cardio-
vascular risk factors has a 2% chance of experiencing a myo-
cardial infarction or stroke over the next 10 years (QRISK:
https://qrisk.org/three/). In this context, a 34% CHD uplift (as
noted in WHI for a women with an intact uterus treated with
combined MHT [8]) will not be particularly clinically
significant (final absolute risk 2.68%). Whilst the lifetime
impact of, for example, a 5-year course of MHT from the
age of menopause is not known, when absolute risks are con-
sidered, the use of MHT in menopausal women at low base-
line cardiovascular risk seems a reasonable option. In terms of
other medications used for bone protection, raloxifene is also
associated with an increased risk of thromboembolic disease,
at the same order of magnitude; bisphosphonates and
denosumab have been associated with rare but serious side
effects such as osteonecrosis of the jaw and atypical femoral
Fig. 2 Treatment options at
different levels of baseline
fracture risk (reused with
permission from [5]). Note that
risk categories do not specifically
correspond to age or menopause
status. LOEP local osteo-
enhancement procedure
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fractures; intravenous bisphosphonates and denosumab may
lead to symptomatic hypocalcaemia; romosozumab was asso-
ciated with increased risk of cardiovascular side effects in one
of its key trials [3, 78]. Finally, strontium ranelate, for which
the licence was restricted by the European Medicines
Authority on the basis of a signal for increased risk of myo-
cardial infarction and subsequently voluntarily withdrawn (al-
though now back on the market as a generic preparation), is
also associated with increased risk of deep vein thrombosis
[79]. This wider context, taken with the logistic issues and
risks of oesophageal ulceration associated with improper use
of oral bisphosphonates, should lead to a more nuanced ap-
praisal of the benefit-risk balance for MHT. Taking all the
evidence together then, MHT is most strongly supported for
the primary indication of prevention of menopausal symp-
toms. Clearly in this context, it may also be viewed as having
the added benefit of preventing bone loss and reducing frac-
ture risk. The benefit-risk balance for a primary indication of
fracture prevention is less clearly defined, and we suggest that
in recently postmenopausal women for whom maintenance of
skeletal health is a clinical priority, whilst MHT might be
considered in those at low risk of cardiovascular disease,
thromboembolic disease and breast cancer as a first line ther-
apy, ultimately further research of MHT in the context of a
long term osteoporosis management strategy is required. The
detailed exposition of the clinical assessment of menopausal
symptoms and their specific treatment (with associated risks)
is beyond the scope of this article, but is very comprehensively
summarized in the various sets of guidance from international
and national bodies described in the preceding section.
Conclusion
The evidence surrounding the use of MHT is complex and
spans a wide range of often conflicting findings from obser-
vational studies and randomized trials. The field has been
beset with highly publicized controversies, which have seen
MHT use decline sharply following initial WHI results, with
something of a move towards rehabilitation of this interven-
tion through subsequent analyses. MHT has a clear role in the
treatment of menopausal symptoms and for manymenopausal
women, use of MHT commenced at the time of, or shortly
after, menopause, under the age of 60 years, may be consid-
ered as an option, in this context, to achieve the additional
benefit of maintenance of bone health where specific bone
active medications are not warranted. Risk assessment should
be individualized, taking into account baseline risk of breast
cancer, together with that of cardiovascular, cerebrovascular
and thromboembolic events, in addition to fracture risk. Such
assessment should be undertaken in the context ofmenopausal
symptoms and detailed discussion with the patient to reach an
optimal understanding of the benefit-risk balance. Nuances
such as the distinction in associations with outcome according
to whether oestrogen is opposed or unopposed, and thus the
relevance of prior hysterectomy and the use of different
oestrogens and progestogens, doses and routes of administra-
tion, are all important considerations. Clearly, it is important
to use preparations that have documented anti-fracture effica-
cy if bone protection is desired, and the approach chosen
should be tailored to the individual benefit-risk balance.
Used in this way, we suggest that the evidence supports the
consideration of MHT as a means of achieving bone protec-
tion and fracture prevention in the context of a primary indi-
cation for menopausal symptom treatment, in recently post-
menopausal women at low baseline risk of cardiovascular
disease, cerebrovascular disease, thromboembolic disease
and breast cancer.
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